Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 5 recruiting now early-phase tilt small index

Stage III Ovarian Cancer AJCC v8: early-phase trial registry

5 of 10 indexed Stage III Ovarian Cancer AJCC v8 trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #1,724 of 28,707 conditions by registered trial count.

10 US clinical trials · 5 currently recruiting · #1,724 of 28,707 conditions by registered trial count

Stage III Ovarian Cancer AJCC v8: 10 US clinical trials tracked, 5 recruiting.

Stage III Ovarian Cancer AJCC v8 is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 5 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most active sponsor is Ohio State University Comprehensive Cancer Center, running 2 of these trials.

Enrollment posture brief

Registry condition stage-iii-ovarian-cancer-ajcc-v8

OPEN 5 | RECR 50% | LATE 1 | EARLY 6 | RANK #1724 | SPON 2

Nearest open-share peer: Abdominal Aortic Aneurysms (50% recruiting · 6 trials)

Acute Leukemia of Ambiguous 80%Stage III Ovarian Cancer (th…50%Achondroplasia40%Accelerated Phase Chronic My20%Accidental Fall20%
Open-enrollment share among volume-matched conditions near Stage III Ovarian Cancer AJCC v8

Stage III Ovarian Cancer AJCC v8 lists 5 open slots (50% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Stage III Ovarian Cancer AJCC v8 on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Stage III Ovarian Cancer AJCC v8 is recruiting above its size-band peers.

    5 of 10 indexed trials (50%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Stage III Ovarian Cancer AJCC v8 research.

    Ohio State University Comprehensive Cancer Center accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.

  3. Most Stage III Ovarian Cancer AJCC v8 trials plan to enrol fewer than 100 people.

    Median target enrolment is 45 among the 10 trials that report a genuine target (sentinel values excluded). 6 of those (60%) plan for fewer than 100 participants.

  4. Stage III Ovarian Cancer AJCC v8 research is mostly interventional.

    9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 14Phase 22Phase 31

Open and recent trials

10 total, page 1 of 1

RECRUITING 250 participants

Developing a Test of Uterine Lavage for the Detection of Ovarian Cancer

Massachusetts General Hospital

NCT04794322

RECRUITING Early Phase 1 161 participants

Effects of a Probiotic Intervention on the Gut and Vaginal Microbiome in Patients With Advanced or Recurrent Ovarian Cancer Undergoing Treatment With Platinum Chemotherapy

Ohio State University Comprehensive Cancer Center

NCT07144826

RECRUITING NA 120 participants

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

Roswell Park Cancer Institute

NCT06855706

RECRUITING Early Phase 1 45 participants

Hyperthermic Intraperitoneal Chemotherapy With Cisplatin During Surgery or Cisplatin Before Surgery for the Treatment of Stage III or IV Ovarian, Fallopian Tube or Peritoneal Cancer

Ohio State University Comprehensive Cancer Center

NCT05415709

RECRUITING Phase 2 40 participants

Pembrolizumab in Treating Participants With Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability

Rutgers, The State University of New Jersey

NCT03428802

ACTIVE NOT RECRUITING Phase 3 450 participants

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NRG Oncology

NCT04095364

ACTIVE NOT RECRUITING Phase 2 30 participants

A Precision Medicine Approach (SMMART-ACT) for the Treatment of Patients With Advanced Sarcoma, Prostate, Breast, Ovarian or Pancreatic Cancer

OHSU Knight Cancer Institute

NCT06630325

ACTIVE NOT RECRUITING Phase 1 25 participants

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer

National Cancer Institute (NCI)

NCT05276973

ACTIVE NOT RECRUITING NA 23 participants

e-Health Intervention (Day-by-Day) for the Management of Fear of Progression in Women With Stage III or IV Gynecologic Cancer: A Pilot Study

City of Hope Medical Center

NCT05786456

ACTIVE NOT RECRUITING Early Phase 1 15 participants

Olaparib in Treating Patients With Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer Before Surgery

M.D. Anderson Cancer Center

NCT03943173

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 1

Named interventions

Most-linked intervention names on Stage III Ovarian Cancer AJCC v8 records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Carboplatin Drug
4 trials
Biospecimen Collection Procedure
3 trials
Questionnaire Administration Other
2 trials
Paclitaxel Drug
2 trials
Biopsy Procedure
2 trials
Telephone-Based Intervention Behavioral
1 trials
Informational Intervention Other
1 trials
Discussion Procedure
1 trials

US sites by state

Facility locations filed on Stage III Ovarian Cancer AJCC v8 trials. A trial with sites in several states counts in each.

Ohio 3 trials
California 3 trials
New York 2 trials
Arkansas 2 trials
Wisconsin 1 trials
Washington 1 trials
Virginia 1 trials
Texas 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Stage III Ovarian Cancer AJCC v8 page

10 registered trials, 5 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Stage III Ovarian Cancer AJCC v8 condition card totals 10 registered trials; most-linked intervention Carboplatin; top US site state Ohio. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.